Literature DB >> 33411531

Simple Secondary Amines Inhibit Growth of Gram-Negative Bacteria through Highly Selective Binding to Phenylalanyl-tRNA Synthetase.

Vadim Baidin1, Tristan W Owens1, Michael B Lazarus2, Daniel Kahne1.   

Abstract

Antibiotics to treat drug-resistant Gram-negative infections are urgently needed but challenging to discover. Using a cell-based screen, we identified a simple secondary amine that inhibited the growth of wild-type Escherichia coli and Acinetobacter baumannii but not the growth of the Gram-positive organism Bacillus subtilis. Resistance mutations in E. coli and A. baumannii mapped exclusively to the aminoacyl-tRNA synthetase PheRS. We confirmed biochemically that the compound inhibited PheRS from these organisms and showed that it did not inhibit PheRS from B. subtilis or humans. To understand the basis for the compound's high selectivity for only some PheRS enzymes, we solved crystal structures of E. coli and A. baumannii PheRS complexed with the inhibitor. The structures showed that the compound's benzyl group mimics the benzyl of phenylalanine. The other amine substituent, a 2-(cyclohexen-1-yl)ethyl group, induces a hydrophobic pocket in which it binds. Through bioinformatic analysis and mutagenesis, we show that the ability to induce a complementary hydrophobic pocket that can accommodate the second substituent explains the high selectivity of this remarkably simple molecular scaffold for Gram-negative PheRS. Because this secondary amine scaffold is active against wild-type Gram-negative pathogens but is not cytotoxic to mammalian cells, we suggest that it may be possible to develop it for use in combination antibiotic therapy to treat Gram-negative infections.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33411531      PMCID: PMC7853427          DOI: 10.1021/jacs.0c11113

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  18 in total

Review 1.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

2.  Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.

Authors:  Karen O'Dwyer; Aaron T Spivak; Karen Ingraham; Sharon Min; David J Holmes; Charles Jakielaszek; Stephen Rittenhouse; Alan L Kwan; George P Livi; Ganesh Sathe; Elizabeth Thomas; Stephanie Van Horn; Linda A Miller; Monique Twynholm; John Tomayko; Marybeth Dalessandro; Madelyn Caltabiano; Nicole E Scangarella-Oman; James R Brown
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

Review 3.  Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.

Authors:  Peter M Hawkey; Roderic E Warren; David M Livermore; Cliodna A M McNulty; David A Enoch; Jonathan A Otter; A Peter R Wilson
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

4.  Crystal structures of phenylalanyl-tRNA synthetase complexed with phenylalanine and a phenylalanyl-adenylate analogue.

Authors:  L Reshetnikova; N Moor; O Lavrik; D G Vassylyev
Journal:  J Mol Biol       Date:  1999-04-02       Impact factor: 5.469

5.  Idiosyncrasy and identity in the prokaryotic Phe-system: crystal structure of E. coli phenylalanyl-tRNA synthetase complexed with phenylalanine and AMP.

Authors:  Inbal Mermershtain; Igal Finarov; Liron Klipcan; Naama Kessler; Haim Rozenberg; Mark G Safro
Journal:  Protein Sci       Date:  2011-01       Impact factor: 6.725

6.  Structure at 2.6 A resolution of phenylalanyl-tRNA synthetase complexed with phenylalanyl-adenylate in the presence of manganese.

Authors:  R Fishman; V Ankilova; N Moor; M Safro
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-10-25

7.  Phenylalanyl transfer ribonucleic acid synthetase from Escherichia coli B. Potent inhibition by analogues of N-benzyl-2-phenylethylamine.

Authors:  R T Anderson; D V Santi
Journal:  J Med Chem       Date:  1976-11       Impact factor: 7.446

8.  Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.

Authors:  Nobutaka Kato; Eamon Comer; Tomoyo Sakata-Kato; Arvind Sharma; Manmohan Sharma; Micah Maetani; Jessica Bastien; Nicolas M Brancucci; Joshua A Bittker; Victoria Corey; David Clarke; Emily R Derbyshire; Gillian L Dornan; Sandra Duffy; Sean Eckley; Maurice A Itoe; Karin M J Koolen; Timothy A Lewis; Ping S Lui; Amanda K Lukens; Emily Lund; Sandra March; Elamaran Meibalan; Bennett C Meier; Jacob A McPhail; Branko Mitasev; Eli L Moss; Morgane Sayes; Yvonne Van Gessel; Mathias J Wawer; Takashi Yoshinaga; Anne-Marie Zeeman; Vicky M Avery; Sangeeta N Bhatia; John E Burke; Flaminia Catteruccia; Jon C Clardy; Paul A Clemons; Koen J Dechering; Jeremy R Duvall; Michael A Foley; Fabian Gusovsky; Clemens H M Kocken; Matthias Marti; Marshall L Morningstar; Benito Munoz; Daniel E Neafsey; Amit Sharma; Elizabeth A Winzeler; Dyann F Wirth; Christina A Scherer; Stuart L Schreiber
Journal:  Nature       Date:  2016-09-07       Impact factor: 49.962

Review 9.  Drugging tRNA aminoacylation.

Authors:  Joanne M Ho; Erol Bakkalbasi; Dieter Söll; Corwin A Miller
Journal:  RNA Biol       Date:  2018-02-02       Impact factor: 4.652

10.  Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase.

Authors:  Sumiti Vinayak; Rajiv S Jumani; Peter Miller; Muhammad M Hasan; Briana I McLeod; Jayesh Tandel; Erin E Stebbins; Jose E Teixeira; Julien Borrel; Arthur Gonse; Mingliang Zhang; Xianshui Yu; Amy Wernimont; Chris Walpole; Sean Eckley; Melissa S Love; Case W McNamara; Manmohan Sharma; Amit Sharma; Christina A Scherer; Nobutaka Kato; Stuart L Schreiber; Bruno Melillo; Boris Striepen; Christopher D Huston; Eamon Comer
Journal:  Sci Transl Med       Date:  2020-09-30       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.